Currently FDA-approved Alzheimer's medications are donepezil, rivastigmine, galantamine, memantine, lecanemab (Leqembi), and donanemab (Kisunla). The first four help manage symptoms, while lecanemab and donanemab target amyloid buildup in early symptomatic disease. Alzheimer's disease slowly damages memory, thinking, and daily function.
Treatment now falls into two groups: daily symptom drugs and amyloid-directed antibodies that require careful patient selection. Aducanumab (Aduhelm) is no longer a current option after its approval was withdrawn effective Nov. 1, 2024.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official notice from FDA — Use this primary source to verify the official announcement.
- Read the official guidance from FDA — Use this primary source to verify the official guidance.
Table of Contents
- Drugs that support memory symptoms
- Options for moderate-to-severe symptoms
- What makes Leqembi and Kisunla different
- Who can receive amyloid antibody treatment
Drugs that support memory symptoms
Donepezil, rivastigmine, and galantamine are cholinesterase inhibitors for mild-to-moderate symptoms. According to the Alzheimer's Association, they preserve acetylcholine in current medications guide current medications guide. Acetylcholine is a brain chemical that carries memory signals between nerve cells.
These drugs do not stop the underlying disease process. They may help attention, recall, and daily tasks for a time. Families often discuss timing, response, and side effects with the prescribing clinician.
Options for moderate-to-severe symptoms
Memantine is an NMDA-receptor antagonist approved for moderate-to-severe Alzheimer's. NMDA refers to a brain receptor system involved in learning and memory. The drug helps regulate abnormal brain signaling tied to later-stage symptoms.
It is also sold in a memantine plus donepezil combination for later-stage symptoms. That combination can simplify dosing when both drugs are prescribed. Clinicians match the choice to stage, tolerance, and care goals.
What makes Leqembi and Kisunla different
Leqembi (lecanemab-irmb) is an amyloid-beta-directed antibody for Alzheimer's. The U.S. FDA gave accelerated approval on Jan. 6, 2023 in its accelerated approval announcement.
It was the second drug in that mechanistic class. The FDA converted Leqembi to traditional approval on July 6, 2023 after a confirmatory trial verified benefit in early disease. Kisunla (donanemab-azbt) was approved on July 2, 2024 for adults with Alzheimer's. The FDA noted Fast Track, Priority Review, and Breakthrough Therapy designations in its approval notice for Kisunla.
Who can receive amyloid antibody treatment
Leqembi and Kisunla are only for early symptomatic disease with confirmed amyloid pathology. Amyloid pathology means abnormal protein buildup linked to Alzheimer's. Use requires biomarker testing and careful patient selection, not treatment at all stages.
Both drugs carry FDA boxed warnings for amyloid-related imaging abnormalities, called ARIA. ARIA means brain swelling or small bleeds seen on scans. According to FDA safety information, treatment requires MRI monitoring and caution with blood thinners in its drug-safety update on MRI monitoring. Readers considering referral can check these practical points: Ask the memory clinic what tests confirm eligibility and how MRI visits are scheduled.
- symptoms are early, with mild cognitive impairment or mild dementia
- amyloid buildup is confirmed by PET scan or spinal-fluid test
- recent brain MRI and medication review are complete
- regular MRI visits and follow-up care are possible





